Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
Vikram M NarayanStephen A BoorjianMehrdad AlemozaffarBadrinath R KonetyNeal D ShoreLeonard G GomellaAshish M KamatTrinity J BivalacquaJeffrey S MontgomerySeth P LernerJoseph E BusbyMichael PochPaul L CrispenGary D SteinbergAnne K SchuckmanTracy M DownsJoseph MashniBrian R LaneGennady BratslavskyLawrence I KarshMichael E WoodsGordon BrownDaniel CanterAdam LucheyYair LotanBrant A InmanMichael B WilliamsMichael S CooksonSam S ChangAlexander I SankinMichael A O'DonnellDavid SawutzRichard PhilipsonNigel R ParkerSeppo Yla-HerttualaDorte RehmJørn S JakobsenKristian JuulColin P N DinneyPublished in: The Journal of urology (2024)
At 60 months, Nadofaragene firadenovec-vncg allowed bladder preservation in nearly half of the patients and proved to be a safe option for BCG-unresponsive NMIBC.